Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other neoplasm 1

Conditions

Precancerous Conditions 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Whole-Body Irradiation 4Sulindac 4Peripheral Blood Stem Cell Transplantation 4Methotrexate 4fludarabine phosphate 3Selenium 3Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 3Cetuximab 3Biopsy 3Tacrolimus 2Sirolimus 2Radiotherapy, Intensity-Modulated 2Polymerase Chain Reaction 2Oxycodone 2Mycophenolic Acid 2Melphalan 2Gene Expression Profiling 2Etoposide 2Darbepoetin alfa 2Cyclosporine 2Cyclophosphamide 2Cisplatin 2Busulfan 2Aspirin 2Aminolevulinic Acid 2Albumin-Bound Paclitaxel 2vandetanib 1soybean oil, phospholipid emulsion 1ruxolitinib 1polyphenon E 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Iloprost × Other neoplasm × Clear all
NCT00084409 2020-05-14

Iloprost in Preventing Lung Cancer in Patients at High Risk for This Disease

University of Colorado, Denver

Phase 2 Completed
152 enrolled 18 charts
Other neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Precancerous Conditions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡